Syndrome of “empty” sella

Dostinex-0.5-mg Dostinex is prescribed to prevent physiological lactation and suppression of postpartum lactation in the following cases:

– if a mother can not breastfeed, or if breastfeeding is contraindicated to a mother or a child;
– in stillbirth or abortion.

Dostinex is also nominated for the treatment of hyperprolactinemia, which manifests itself as a violation of the menstrual cycle (amenorrhea, oligomenorrhea, anovulation), infertility, galactorrhea in women or even impotence, decreased libido in men. Dostinex is indicated for the treatment of patients with pituitary adenomas (micro-and makroprolaktinomami), idiopathic hyperprolactinemia or a syndrome of “empty” sella, which are the main pathological conditions associated with hyperprolactinemia.

Dosing and Administration

Dostinex is taken orally, preferably at mealtimes. To prevent lactation the drug should be taken at a dose of 1 mg (2 tablets) once the first day after birth. For the suppression of established lactation appoint 0.25 mg (1 / 2 tablets) 2 for 2 days (total dose is 1 mg). To reduce the risk of orthostatic hypotension in lactating patients – a single dose of Dostinex should not exceed 0.25 mg. For the treatment of disorders associated with hyperprolactinemia, the drug is prescribed in a dose of 0.5 mg per week in 1 or 2 doses (1 / 2 tablet, for example, Monday and Thursday). Increase of weekly dose should be gradual – 0.5 mg at intervals of 1 month to achieve the optimal therapeutic effect. The average therapeutic dose is 1 mg per week, but can range from 0.25 mg to 2 mg per week. The maximum dose for patients with hyperprolactinemia is 4.5 mg per week.

Be the first to comment on "Syndrome of “empty” sella"

Leave a comment

Your email address will not be published.